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Abstract 
Background: Radiofrequency ablation (RFA) is a standard therapy for the 
treatment of hepatocellular carcinoma (HCC) numbering 3 or fewer tumors 
of up to 3 cm (early stage HCC); when RFA is unsuccessful or unfeasible, 
transcatheter arterial chemoembolization (TACE) has often been performed.  
However, little information about the outcome of TACE for early stage HCC 
has been reported and it is hard to decide whether to perform additional 
treatment following TACE in these difficult conditions.  The aim of this 
study was to determine the risk factors of local or intrahepatic distant 
recurrence after TACE in early stage HCC. 
Methods: Among 1,560 newly diagnosed HCC patients who were admitted to 
Okayama University Hospital, 43 early stage HCC patients who received 
only TACE of at least one nodule were enrolled in this study.  We analyzed 
the risk factors for local and distant recurrence by Cox proportional hazard 
model. 
Results: The local recurrence rates and intrahepatic distant recurrence rates 
at 3 months, 6 months, and 1 year were 18.6%, 33.4%, and 61.8%, and 2.8%, 
2.8%, and 10.2%, respectively.  Among 12 parameters examined, 
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heterogeneous lipiodol uptake (risk ratio 3.38; 95% confidence interval 
1.14-10.60) and high serum des-gamma-carboxy prothrombin (DCP) (2.58; 
1.03-7.14) were significantly correlated with local recurrence, and multiple 
tumors (10.64; 1.76-93.75) was significantly correlated with intrahepatic 
distant recurrence.   
Conclusions: Heterogeneous lipiodol uptake, high serum DCP and multiple 
tumors are risk factors for recurrence in patients with early HCC who have 
undergone palliative TACE. 
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Introduction 
Hepatocellular carcinoma (HCC) has become increasingly detected at an 
early stage with the growing use of surveillance systems.  The guidelines 
established by the American Association for the Study of Liver Disease 
(AASLD) [1], European Association for the Study of the Liver (EASL) [2], and 
the Japanese “Evidence-Based Guidelines” recommend local treatment [3-4], 
such as radiofrequency ablation (RFA) or operation, for HCCs numbering 3 
or fewer tumors of up to 3 cm with good liver functional reserve and 
performance status.  Additionally, RFA combined with transcatheter 
arterial chemoembolization (TACE) has been reported to be an efficient and 
safe treatment that provides an overall survival rate similar to those 
achieved with surgical resection [5-7].  If HCC is hypervascular tumor, most 
cases of HCCs numbering 3 tumors or fewer of up to 3 cm are often subjected 
to sequential TACE followed by RFA, percutaneous ethanol injection therapy 
(PEIT), or operation regardless of the size because TACE is expected to 
enhance the efficacy of local therapy by reducing arterial blood flow [8]. 
Occasionally, several factors such as poor liver functional reserve, difficult 
location for RFA treatment, and presence of severe associated diseases in the 
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elderly or those rejecting treatment result in the selection of only TACE, 
even in candidates for local therapies.  TACE is known to be effective for 
inoperable HCC [9-10]; however, little information has been reported about 
TACE for early stage HCC and it is hard to decide whether to perform 
additional treatment following TACE in these difficult conditions.   
The objective of this retrospective cohort study was to determine 
whether only TACE for HCC numbering 3 tumors or fewer of up to 3 cm 
could control HCC by revealing the recurrence rate and the risk factors of 
local or intrahepatic distant recurrence in such cases.   
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Subjects and Methods 
Patients  
Patients were enrolled from among 1,560 newly diagnosed HCC patients 
who were admitted to Okayama University Hospital between 2002 and 2010.  
Inclusion criteria were as follows: (1) no previous treatment of HCC, (2) 3 or 
fewer nodules of up to 3 cm (early stage HCC), (3) at least one nodule treated 
only by TACE as an initial treatment, (4) no planned local treatment 
performed such as RFA, PEIT, or operation within 30 days of TACE, (5) no 
vascular invasion, and (6) no extrahepatic metastasis.  Exclusion criteria 
were (1) complete cures of all nodules with RFA, PEIT, or operation and (2) 
follow-up period less than 1 year.  Finally, 43 patients was selected and 
enrolled in this study.  Of these patients, 6 died in the follow-up period.  
Five of these died due to liver disease and 1 died of heart failure.  Informed 
consent was obtained from all patients in this study for the use of their 
clinical data.  The study protocol conformed to the ethical guidelines of the 
World Medical Association Declaration of Helsinki and was approved by the 
ethical committee of the institute (approval # 458). 
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Diagnosis 
HCC was diagnosed in accordance with AASLD guidelines.  The diagnostic 
criteria for HCC via imaging were based on hyperattenuation at the artery 
phase, hypoattenuation at the portal phase by dynamic computed tomography 
(CT) or magnetic resonance imaging (MRI), and tumor stain on angiography.  
Sonazoid ultrasonography (US) and/or Gadolinium ethoxybenzyl magnetic 
resonance imaging (Gd-EOB-MRI) was performed in 30 (69.8%) cases.  When 
we could not diagnose HCC by only imaging, fine needle biopsy using 
abdominal US was performed as histological proof (3 cases).  Recurrence of 
HCC was diagnosed in the same way at the initial diagnosis. 
 
Treatment 
TACE was performed using the Seldinger technique followed by arterial 
embolization.  After introducing a 4-Fr catheter through the femoral artery, 
hepatic arteriography and superior mesenteric arterial portovenography 
were performed to evaluate portal flow and location of tumors.  When portal 
flow was sufficient, a 1.8-Fr or a 2.0-Fr microcatheter was placed in the 
feeding arteries at the closest point from the HCC.  An emulsion consisting 
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of 30 to 60 mg of epirubicin (Kyowa-Hakko, Japan) and 2 to 6 ml of iodized oil 
(Lipiodol Ultrafluid; Terumo, Japan) was injected into the artery supplying 
blood to the tumor, followed by embolization with 1mm gelatin sponge 
particles (Gelfoam; Nihonkayaku, Japan).  After embolization, CT 
angiography was performed to determine the extent of vascular occlusion 
and to assess blood flow in other arterial vessels.  Patients were observed 
carefully, and analgesia (Pentazocine; Astellas, Japan) was administered if 
necessary.  
  Lipiodol uptake was divided into two groups of homogeneous and 
heterogeneous by plain CT after TACE. Homogeneous was defined by 
complete uptake of lipiodol in the tumor without any defect, and CT value in 
these cases was over 200 Hounsfield Unit.  The rest was considered as 
heterogeneous.  Two experienced investigators (K.N. and H.O.) reviewed 
the images of CT and evaluated the lipiodol uptake.  If the two investigators 
had different diagnoses, they discussed the difference and reached 
agreement.  
 
Follow up 
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Patients were assessed every one to three months by serum biochemistry, 
dynamic CT, dynamic MRI, or US.  Local recurrence was defined as the 
appearance of viable tumor in contact with or inside the treated area.  
Intrahepatic distant recurrence was defined as the occurrence of a new HCC 
in the liver that did not meet the definition of local recurrence.  When 
recurrence was detected, TACE, RFA, PEIT, or surgical resection was 
performed depending on the condition of the recurrence and background 
liver function.  Patients were followed until loss to follow up, death, or 
January 31, 2011.  
 
Statistical analysis 
The following 12 parameters were used for analyzing the risk factors for 
recurrence: age, sex, viral markers (hepatitis B virus surface antigen and 
hepatitis C virus antibody), alcohol intake, liver function, size of tumors, 
number of tumors, location of tumors (within 10 mm of the surface of the liver 
or not), serum tumor markers (alpha-fetoprotein (AFP) and 
des-gamma-carboxy prothrombin (DCP)), and the status of lipiodol uptake. 
  Recurrence rates were estimated using the Kaplan-Meier method and 
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differences between groups were compared using the log-rank test.  The Cox 
proportional hazard model was used to analyze the predisposing factors for 
recurrence.  All statistical analyses were performed using JMP version 9 
(JMP Japan, Tokyo, Japan).  All reported P values are 2-sided, with P<0.05 
considered statistically significant. 
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Results 
Patient background 
A total of 43 patients met the criteria of this study.  The total number of 
HCC nodules was 54.  There were 27 males (63%) and 16 females (37%) 
aged 50-85 years (mean: 71 years), and 34 patients (79%) were infected with 
hepatitis C virus and 6 (14%) with hepatitis B virus.  Twenty-three patients 
(53%) were habitual drinkers.  Thirty-four patients (79%) had a single 
tumor in the initial treatment.  Thirty-six patients (84%) had recurrence 
(Table 1).  Eleven (26%), 23 (53%), and 9 (21%) patients were treated with 
only TACE because of poor liver functional reserve, difficult location for RFA, 
and old age, respectively.  Among 11 patients who had poor liver function, 1 
patient was Child C and 10 patients was Child B.  Although the Japanese 
guideline for treatment of HCC indicates that RFA/Operation was 
recommended for the treatment of small HCC with Child A/B stage, these 10 
Child B patients had worse condition like uncontrollable ascites or low 
albumin so that it was quite difficult to perform RFA/Operation.  Among 23 
patients who had difficult location for RFA, the nodules were located beside 
portal vein in 5 patients, digestive tract in 4 patients, gallbladder in 4 
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patients, inferior vena cava in 3 patients, collateral veins on the surface of 
liver in 3 patients, bile duct in 3 patients, and beside heart in 1 patient. 
 
Recurrence rate 
Local recurrence and intrahepatic distant recurrence were observed in 29 
patients and 14 patients, respectively, and in these cases, 7 involved both 
local and intrahepatic distant recurrences at the same time. 
The total recurrence rates at 3 months, 6 months, and 1 year were 20.9%, 
35.3%, and 68.5%, respectively.  The local recurrence rates and intrahepatic 
distant recurrence rates at 3 months, 6 months, and 1 year were 18.6%, 
33.4%, and 61.8%, and 2.8%, 2.8%, and 10.2%, respectively (Fig. 1).  
Thirteen patients had local recurrences within 180 days.  Eleven patients 
and 11 patients received RFA and TACE for the therapy of local recurrence, 
respectively.  Eight patients, 5 patients, and 1 patient received RFA, TACE, 
and PEIT for the therapy of intrahepatic distant recurrence, respectively.  
No difference of the therapies was observed between the local recurrence 
group and the distant recurrence group.  
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Factors related to local recurrence 
Among 12 factors analyzed, heterogeneous lipiodol uptake (risk ratio 3.19; 
95% confidence interval 1.41-7.90; P=0.004) and high serum DCP (2.37; 
1.06-5.83; 0.034) were correlated with local recurrence by univariate analysis.  
The factor of location was not associated with local recurrence on univariate 
analysis.  Factors exhibiting significance in the univariate analysis and 
reported to be correlated with recurrence, namely, DCP, age, number of HCC, 
liver function, size of HCC, extent of lipiodol uptake, HCV, and location of 
HCC, were further analyzed using the Cox multivariate proportional hazard 
model [11-20].  On multivariate analysis, only heterogeneous lipiodol 
uptake (risk ratio 3.38; 95% confidence interval 1.14-10.60; P=0.027) and 
high serum DCP (2.58; 1.03-7.14; 0.042) were significantly correlated with 
local recurrence (Table 2). 
 
Factors related to intrahepatic distant recurrence 
In the same way, among 12 factors analyzed, the factor of multiple tumors 
(3.98; 1.02-13.50; 0.047) was correlated with intrahepatic distant recurrence 
by univariate analysis.  On multivariate analysis with serum DCP, age, 
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tumor number, Child-Pugh score, tumor size, lipiodol uptake, HCV, and 
tumor location, multiple tumors (10.64; 1.76-93.75; 0.010) was significantly 
correlated with recurrence (Table 3). 
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Discussion 
While RFA is considered as the first choice for the treatment of early stage 
HCC, TACE could be another option when RFA is unsuccessful or unfeasible. 
Livraghi et al. reported that RFA was not feasible in 6.0% of patients because 
of a high-risk tumor location or poor detection on ultrasonography [21].  
However, it is hard to decide to treat these patients with additional 
locoregional therapy because there have been few reported studies 
examining the outcomes of these patients in detail.    
In this study, the clinical course of 43 patients treated with palliative 
TACE for HCC numbering 3 tumors or fewer of up to 3 cm was examined.  
Over 80% of the patients (36/43, 84%) had recurrence and most of them 
(29/36, 80%) exhibited local recurrence.  The rate was higher than that of 
local ablation.  The recurrence rates of the patients treated with 
RFA/operation at 3 months, 6 months, and 1 year in our institution during 
the same period were 2.8%, 9.6%, and 24.5%, respectively. 
Cases with heterogeneous lipiodol uptake and high serum DCP were 
significantly correlated with local recurrence, whereas multiple tumor was 
significantly correlated with intrahepatic distant recurrence.   
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The risk factors for recurrence after TACE in patients with HCC have been 
described in several reports.  These include extent of lipiodol uptake, 
location of HCC, size of HCC, tumor markers, viral markers, number of HCC, 
age, and liver function [11-20].  However, most of these studies were on 
TACE for advanced HCC.  In this study, we examined the risk factors for 
early stage HCC and revealed that only the extent of lipiodol uptake and 
serum DCP level were correlated with local recurrence, which is the most 
common type of recurrence after TACE.  In cases of early stage HCC, most 
HCC might be highly differentiated and less invasive so that the tumor can 
be controlled merely by complete obstruction of blood supply.  Then, only 
high DCP is an additional risk factor because HCC with high DCP showed a 
poorer differentiation grade [22].  The results suggested that it is better to 
treat early stage HCC showing high serum DCP as well as incomplete 
lipiodol uptake not only with TACE but also with additional locoregional 
treatment if possible.   
On the other hand, intrahepatic distant recurrence was observed in cases 
with multiple tumors, indicating that some of these tumors were 
intrahepatic metastases and that undetectable small HCC might have 
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already existed.         
  Meta-analysis showed that chemoembolization could improve the survival 
of well-selected patients with unresectable HCC [23]; in addition, there is a 
report that the effect was observed even in HCC with poor liver function [24].  
However, the efficacy of TACE for HCC at an early stage has not been well 
elucidated.  Although we could not show the survival benefit of TACE in 
early stage HCC, to the best of our knowledge, this is the first report about 
the outcome of TACE for HCC numbering 3 tumors or fewer of up to 3 cm.   
While new technologies such as artificial pleural effusion, ascites or 
Real-time Virtual Sonography (RVS) increase the number of patients eligible 
for RFA, the age of HCC patients gradually increases so that more patients 
would be excluded from observation when considering the treatment 
guideline algorithm of HCC owing to the presence of complications and poor 
performance status, among other factors.  Eventually, we could not avoid 
facing the selection of TACE instead of RFA and operation.  This study 
helped us to decide if additional treatment should be considered according to 
the treatment algorithms even in cases with difficult conditions.   
In conclusion palliative TACE for HCC numbering 3 tumors or fewer of up 
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to 3 cm could be effective.  Lipiodol uptake, serum DCP and number of 
tumors (2) are the most important factors to control these HCC numbering 
3 tumors or fewer of up to 3 cm with palliative TACE.  Heterogenous uptake 
should not be left untreated after TACE as much as possible.     
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Table 1  Clinical background of 43 patients 
Demographic variables   
Sex (male)  27 (63%) 
Age (years)  71 (50-85) 
Etiology HCV 34 (79%) 
 HBV 6 (14%) 
 HCV+HBC 2 (4.7%) 
 Alcohol 23 (53%) 
 Unknown 1 (2%) 
Tumor size (mm)  18 (6-30) 
Number of tumors 1 34 (79%) 
 2 7 (16%) 
 3 2 (5%) 
Location (distance from 
surface of the liver) 
10 mm 28 (65%) 
Recurrence local 22 (52%) 
 distant 7 (16%) 
28 
 local+distant 7 (16%) 
 no recurrence 7 (16%) 
Lipiodol uptake homogeneous 23 (53%) 
 heterogeneous 20 (47%) 
AFP (ng/mL)  124.1 (1.6-1539) 
DCP (mAU/mL)  157.7 (12-3450) 
Total bilirubin (mg/dL)  1.09 (0.37-3.13) 
Albumin (g/dL)  3.47 (2.4-4.42) 
ALT (IU/L)  43.5(13-147) 
AST (IU/L)  55.2(23-119) 
Child-Pugh score (A/B/C) 32/10/1 
Numbers in the tables are shown as median (range) unless otherwise noted. 
HCV, positive for hepatitis C virus antibody; HBV, positive for hepatitis B 
virus antigen; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy 
prothrombi; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase.  
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Table 2  Risk factors for local recurrence after TACE 
Variables 
 Univariate  Multivariate 
Risk ratio 
(95% CI) 
P-value 
Risk ratio 
(95% CI) 
P-value 
AFP (>10 ng/mL) 1.46(0.69-3.23) 0.328   
DCP (>28 mAU/mL) 2.37(1.06-5.83) 0.034* 2.58(1.03-7.14) 0.042* 
Age (75 years) 1.04(0.50-2.24) 0.900 1.16(0.42-3.11) 0.769 
Tumor number (2) 1.72(0.66-4.04) 0.249 1.18(0.37-3.26) 0.759 
Child-Pugh score (7) 1.25(0.51-3.74) 0.650 1.65(0.60-5.43) 0.347 
Tumor size (20 mm) 1.58(0.74-3.37) 0.230 1.66(0.70-3.94) 0.245 
Lipiodol uptake 
(heterogeneous) 
3.19(1.41-7.90) 0.004* 3.38(1.14-10.60) 0.027* 
Sex 1.01(0.48-2.23) 0.976   
HCV 2.07(0.74-4.99) 0.153 2.09(0.55-7.65) 0.271 
HBV 0.91(0.32-3.85) 0.882   
Alcohol 0.99(0.47-2.14) 0.975   
Location (within 10 mm from 0.66(0.31-1.47) 0.302 0.80(0.26-2.37) 0.687 
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the liver surface) 
TACE, transcatheter arterial chemoembolization; 95% CI, 95% confidence 
interval; *, significant value.  Other abbreviations are the same as 
described in Table 1.   
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Table 3  Risk factors for distant recurrence after TACE  
Variables  Univariate  Multivariate 
 
Risk ratio 
(95% CI) 
P-value 
Risk ratio 
(95% CI) 
P-value 
AFP (>10 ng/mL) 1.22(0.40-3.85) 0.721   
DCP (>28 mAU/mL) 1.19(0.37-3.83) 0.765 1.73(0.44-7.41) 0.425 
Age (75 years) 2.07(0.67-7.67) 0.211 4.30(0.88-32.60) 0.073 
Tumor number (2) 3.98(1.02-13.50) 0.047* 10.64(1.76-93.75) 0.010* 
Child-Pugh score  (7) 0.70(0.21-3.21) 0.611 0.71(0.16-4.21) 0.688 
Tumor size  (20 mm) 1.09(0.33-3.34) 0.879 1.50(0.33-7.08) 0.594 
Lipiodol uptake 
(heterogeneous) 
1.99(0.61-6.53) 0.250 1.32(0.08-15.76) 0.834 
Sex 2.30(0.76-7.66) 0.138   
HCV 0.45(0.11-3.04) 0.360 0.64(0.08-7.19) 0.688 
HBV 0.49(0.12-3.27) 0.405   
Alcohol 0.60(0.19-1.83) 0.365   
Location (within 10 mm from  0.54(0.17-1.84) 0.304 0.78(0.04-14.50) 0.864 
32 
the liver surface) 
Abbreviations are the same as described in Table 2.
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Figure legend 
Fig. 1  Local and distant recurrence after transcatheter arterial 
chemoembolization.   
The local recurrence rates (solid line) and intrahepatic distant recurrence 
rates (dotted line) at 3 months, 6 months, and 1 year were 18.6%, 33.4%, and 
61.8%, and 2.8%, 2.8%, and 10.2%, respectively. 
Fig.1
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Additional information
